相关实验视频

Updated: Jun 5, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

尼姆玻利德通过调节miRNAs 21,145和221及其向基因表达来减弱肝细胞癌

Balasubramaniyan Vairappan¹, Victor Mukherjee¹, Siva Bala Subramanian¹

¹Liver Diseases Research Lab, Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Dhanvantari Nagar, Puducherry 605006, India.

|December 7, 2024

概括

在患有肝细胞癌 (HCC) 的小鼠中,Nimbolide 治疗减少了与癌症进展相关的特定微RNA (miRNA). 这项研究表明 nimbolide.

科学领域:

肝细胞癌 (HCC) 研究研究
分子瘤学分子瘤学
自然产品疗法自然产品疗法

背景情况:

微RNAs (miRNAs) 在癌症发育中至关重要,作为瘤基因或瘤抑制剂.
尼姆的化合物尼姆玻利德 (Nimbolide) 曾经在小鼠中显示出减弱HCC的潜力.
特定miRNAs (miR-21,miR-145,miR-221) 的调节失调与HCC病变发生有关.

研究的目的:

在HCC小鼠中研究nimbolide对特定miRNAs (21, 145, 221) 的作用.
为了确定宁波利德如何调节与炎症和增殖有关的miRNA基因.
通过准miRNA路径,阐明nimbolide在HCC中的治疗潜力.

主要方法:

肝细胞癌 (HCC) 在小鼠中被诱导.
尼姆玻利德被口服给HCC小鼠四周.
分析了肝脏miRNA表达,紧结蛋白和关键癌症相关基因.

主要成果:

尼博利德治疗显著改变了肝脏miRNA表达,减少miR-21和miR-221,同时增加miR-145.
尼姆玻利德调节了紧密结合蛋白 (克劳丁) 和关键基因 (甲德林,ROCK 1,MMP 9,环林D1,CDK4,NF-κB,TNFα) 的表达.
体内研究证实了关于miRNA调节的体内发现.

结论:

在HCC小鼠中,尼姆玻利德治疗有效地减弱了特定的亲癌miRNAs (miR-21,miR-221) 并支持瘤抑制miR-145.
尼姆玻利德调节影响癌细胞增殖和炎症的miRNA基因,从而抑制HCC的进展.
这项研究强调了尼姆玻利德作为HCC的潜在治疗剂,通过向miRNA途径.

关键词:

在Cadherins的基础上.克劳丁斯克劳丁斯是什么意思在HCC中,HCC是HCC,HCC是HCC.炎症炎症是一种炎症.尼姆玻利德和ROCK 1 1 的使用情况微RNAs 是一个微型RNA.

更多相关视频

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Published on: June 12, 2018

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...